A positive Lyme result on a SNAP 4Dx test means your dog has been exposed to Borrelia burgdorferi, the spirochete bacterium transmitted by blacklegged ticks, and has mounted an immune response. It does not mean your dog is sick. Roughly 90 to 97 percent of dogs that test positive for Lyme exposure never develop clinical illness — a striking contrast with human Lyme disease, where the majority of infected people become symptomatic. When signs do appear in dogs, they usually present 2 to 5 months after the tick bite as a shifting-leg lameness lasting a few days, fever, swollen joints, and lethargy. The standard treatment is doxycycline as the Lyme treatment standard, typically prescribed for about four weeks.

The form to fear is Lyme nephritis — a serious immune-mediated kidney disease that can cause rapid, irreversible renal failure. It disproportionately affects Labrador Retrievers and Golden Retrievers. And because isoxazoline tick preventives kill ticks after they attach but do not block Borrelia transmission before the bite, the Lyme vaccine and tick prevention are complementary strategies, not interchangeable ones.

What does a positive Lyme test on a SNAP 4Dx actually mean?

The SNAP 4Dx test is a point-of-care combination test run during your dog's annual wellness exam. It simultaneously screens for heartworm antigen and antibodies to three tick-borne pathogens: Borrelia burgdorferi (Lyme disease), Anaplasma species, and Ehrlichia species. For a broader overview of all three tick-borne diseases, see the tick-borne diseases in dogs overview.

A positive Lyme line on the SNAP test detects antibodies to the C6 peptide of B. burgdorferi. This is a key design feature: the C6 peptide is expressed only during natural infection, not in response to Lyme vaccination. This means a Lyme-vaccinated dog will not produce a false-positive 4Dx result unless it has also been naturally exposed to the bacteria through a tick bite.

Exposure does not equal disease

This is the most important concept in canine Lyme disease, and it is frequently misunderstood by pet owners. A positive antibody test confirms:

• The dog was bitten by an infected blacklegged tick
• The dog's immune system recognized B. burgdorferi and produced antibodies
• The dog has been exposed

A positive test does not confirm:

• Active infection requiring treatment
• Current clinical illness
• Inevitable future disease

Multiple studies and clinical experience, including data from CAPC and summaries from the AVMA and Ohio State University, consistently show that only about 3 to 10 percent of seropositive dogs ever develop clinical signs. Most dogs clear or control the infection through their immune response and never become ill. This ratio is dramatically different from human Lyme disease, where the majority of infected individuals develop the characteristic erythema migrans rash and may progress to joint, neurologic, or cardiac involvement.

When should a Lyme-positive dog be treated with doxycycline?

The decision to treat depends on whether the dog is showing clinical signs or evidence of organ involvement — not simply on the positive test result.

Asymptomatic Lyme-positive dogs: the watchful-screening approach

For a clinically healthy dog with a positive Lyme antibody test and no symptoms, many veterinarians follow a screening-and-monitoring approach rather than immediate antibiotic therapy:

1. Physical examination — look for lameness, joint swelling, fever, lymph node enlargement
2. Complete blood count and chemistry panel — check for abnormalities suggesting systemic illness
3. Urinalysis with urine protein-to-creatinine ratio (UPC) — screen for proteinuria, the earliest sign of Lyme nephritis. For details on interpreting this test, see screening a Lyme-positive dog for proteinuria
4. Quantitative C6 (QC6) antibody titer — measures the level of C6 antibodies, providing a baseline for monitoring

If the physical exam is normal, blood work is unremarkable, and the urinalysis shows no proteinuria, many veterinarians will elect to monitor rather than treat. The ACVIM 2018 consensus statement on Lyme borreliosis in dogs supports this approach, noting that treatment of clinically healthy seropositive dogs is controversial and that the evidence does not demonstrate clear benefit. Overtreatment with antibiotics carries antimicrobial stewardship concerns without proven patient benefit.

Symptomatic Lyme-positive dogs: when to treat

Treatment with doxycycline is indicated when a seropositive dog shows:

• Shifting-leg lameness — the hallmark clinical sign of Lyme arthritis, typically a sudden-onset lameness that shifts between legs over days
• Fever, lethargy, inappetence — nonspecific systemic signs consistent with active infection
• Joint swelling or pain on palpation
• Proteinuria — urine protein detected on screening, even if the dog appears otherwise well, because proteinuria can signal early Lyme nephritis

The CAPC-recommended treatment protocol is doxycycline administered for 30 days. The ACVIM 2018 consensus supports approximately four weeks of therapy for Lyme arthritis. Most dogs with clinical Lyme disease respond rapidly to doxycycline — fever resolves within 24 to 48 hours, and lameness typically improves within days, though the full antibiotic course must be completed.

What happens after treatment?

Post-treatment monitoring typically includes:

• Re-check QC6 titer 6 months after treatment — a declining titer suggests successful treatment, though antibodies may persist at low levels for years
• Urinalysis and UPC at regular intervals — especially important in breeds at high risk for Lyme nephritis
• Clinical monitoring — report any recurrence of lameness, lethargy, or appetite changes

It is important to understand that doxycycline treatment may not completely eliminate B. burgdorferi from the body. The bacterium has mechanisms that allow it to persist in tissues at low levels even after antibiotic therapy. In most dogs, this low-level persistence does not cause clinical disease, but it means the C6 antibody test may remain positive indefinitely.

What is Lyme nephritis, and why are retrievers at higher risk?

Lyme nephritis — also called Lyme protein-losing nephropathy — is the rare but life-threatening form of canine Lyme disease. It is an immune-mediated kidney disease in which immune complexes (antibody-antigen complexes) deposit in the glomeruli of the kidneys, causing progressive protein loss into the urine, declining kidney function, and potentially fatal renal failure.

Clinical presentation

Unlike Lyme arthritis, which is painful but usually treatable, Lyme nephritis can progress rapidly:

• Proteinuria — excessive protein in the urine, often the first detectable sign
• Edema — swelling of the legs or abdomen due to protein loss
• Weight loss, vomiting, poor appetite — signs of progressive kidney failure
• Azotemia — elevated blood urea nitrogen (BUN) and creatinine indicating reduced kidney function
• Hypertension — elevated blood pressure associated with kidney disease

Lyme nephritis can progress to end-stage kidney failure and death, sometimes rapidly. The prognosis is guarded to poor once advanced nephropathy is established.

The breed skew

Lyme nephritis disproportionately affects certain breeds:

• Labrador Retrievers — the most commonly reported breed
• Golden Retrievers — also overrepresented in case series
• Shetland Sheepdogs and Bernese Mountain Dogs — reported at lower frequency but with possible breed predisposition

The genetic or immunologic basis for this breed susceptibility is not fully understood. One hypothesis is that certain breeds mount an exaggerated immune-complex response to B. burgdorferi antigens, leading to glomerular damage. Regardless of the mechanism, the clinical implication is clear: owners of Labrador Retrievers, Golden Retrievers, and other at-risk breeds in Lyme-endemic areas should be especially diligent about annual screening, and any Lyme-positive dog in these breeds should have urine protein screening even if clinically well.

Monitoring for Lyme nephritis

For Lyme-seropositive dogs in high-risk breeds, recommended screening includes:

• Baseline urinalysis with UPC ratio at the time of positive test
• Annual or semi-annual recheck of UPC ratio
• Immediate workup if proteinuria is detected: full chemistry panel, blood pressure, abdominal ultrasound
• Referral to an internal medicine specialist if nephritis is confirmed

Early detection of proteinuria — before azotemia develops — offers the best chance of intervention, though there is no cure for established Lyme nephritis. Treatment focuses on managing the kidney disease: ACE inhibitors or ARBs for proteinuria, blood pressure management, renal-supportive diet, and monitoring.

Do tick preventives (isoxazolines) prevent Lyme disease?

Not entirely. This is one of the most important nuances in Lyme disease prevention, and it is widely misunderstood.

Isoxazoline tick preventives — including fluralaner (Bravecto), afoxolaner (NexGard), sarolaner (Simparica and Simparica Trio), and lotilaner (Credelio) — are highly effective at killing ticks. They work systemically: the drug is absorbed into the dog's bloodstream, and the tick ingests the drug during its blood meal, which kills the tick. For a full overview of this drug class, see why an isoxazoline tick pill does not fully stop Lyme.

The timing problem

Borrelia burgdorferi transmission requires approximately 24 to 48 hours of tick attachment. Isoxazolines begin killing ticks within hours of attachment, and most ticks are killed before the 48-hour transmission window closes. This means isoxazolines significantly reduce — but do not eliminate — the risk of Borrelia transmission.

The gap exists because:

• Not every tick is killed within the first 24 hours of attachment
• Tick attachment may go unnoticed until the isoxazoline has had time to act
• The speed of Borrelia transmission can vary, and some studies suggest transmission may occasionally begin before the 48-hour mark under certain conditions
• Real-world compliance — missed doses, delayed administration — creates gaps in protection

The openFDA evidence

Data from the openFDA adverse event database provides a measurable signal that isoxazoline tick prevention does not fully prevent Borrelia infection. Reports categorized as "Lack of efficacy (bacteria) — Borrelia" exist for multiple isoxazoline products:

• Afoxolaner (NexGard): 1,941 reports, almost all in dogs
• Sarolaner (Simparica products): 2,678 reports — the large majority come from sarolaner combination products such as Simparica Trio (sarolaner with moxidectin and pyrantel), so this total is inflated relative to a standalone-ingredient count

These are passive surveillance reports — they do not prove that the drug failed or that the drug caused the infection, and they cannot establish an incidence rate. They are also deduplicated by unique report identifier and tallied per ingredient, so a combination product shows up under each of its active ingredients. Even with those caveats, the volume of reports is consistent with the known biology: tick-killing products reduce but do not eliminate Borrelia exposure, particularly in high-prevalence regions where tick burden is heavy.

The practical conclusion: isoxazoline tick preventives reduce Lyme risk but are not a substitute for Lyme vaccination in high-risk areas. The two strategies are complementary.

Should my dog get both the Lyme vaccine and a tick preventive?

In Lyme-endemic areas, the answer for most at-risk dogs is yes — both. Here is why:

The Lyme vaccine

Several USDA-licensed Lyme vaccines are available, most based on outer surface protein A (OspA) of B. burgdorferi. The vaccine works by a unique mechanism: antibodies produced in the vaccinated dog enter the tick during the blood meal and kill the spirochete inside the tick's gut before it can be transmitted to the dog. The vaccine is classified as non-core (lifestyle) by the AAHA and WSAVA vaccine guidelines, recommended for dogs living in or traveling to endemic areas.

The vaccination protocol typically involves:

• Two initial doses given 2 to 4 weeks apart
• Annual boosters thereafter
• Vaccination does not cause a positive result on the C6-based SNAP test

The complementary stack

Strategy	What it does	What it does not do
Isoxazoline tick preventive	Kills ticks that attach, reducing Borrelia exposure	Does not prevent all Borrelia transmission before tick death
Lyme vaccine	Produces antibodies that kill Borrelia inside the tick's gut	Does not kill or repel ticks; no protection against other tick-borne diseases
Tick-check and removal	Removes attached ticks before transmission window	Requires finding the tick; not always practical for thick-coated dogs

No single strategy provides complete protection. In high-risk areas, combining tick prevention with Lyme vaccination provides the most comprehensive defense. For tick prevention as one part of the Lyme stack, the preventive product roundup covers available options.

Regional considerations

The decision to vaccinate is region-dependent. CAPC reports dog seroprevalence data that varies dramatically by region:

• Northeast and Upper Midwest — seroprevalence reaching approximately 13.3 percent, the highest in the country. Lyme vaccination is strongly recommended in these areas.
• Mid-Atlantic and Southeast — expanding risk as blacklegged tick populations move southward
• Pacific Northwest — moderate and increasing risk from Ixodes pacificus
• West and Southwest — seroprevalence approximately 1.4 percent; Lyme vaccination may not be justified for dogs that do not travel

Your veterinarian will factor in your region, your dog's outdoor exposure level, and local tick prevalence data when making the vaccine recommendation.

How is Lyme disease different from anaplasmosis and ehrlichiosis?

Dogs in tick-endemic areas frequently test positive for more than one tick-borne pathogen, because the same tick species can carry multiple organisms. Understanding the differences helps frame the veterinary conversation:

Feature	Lyme disease	Anaplasmosis	Ehrlichiosis
Pathogen	Borrelia burgdorferi (spirochete)	Anaplasma phagocytophilum or A. platys	Ehrlichia canis or E. ewingii
Primary vector	Blacklegged tick (Ixodes)	Blacklegged tick (Ixodes) or brown dog tick	Lone star tick or brown dog tick
Most infected dogs symptomatic?	No (3–10%)	No (many are subclinical)	Variable; chronic form can be severe
Hallmark sign	Shifting-leg lameness	Fever, thrombocytopenia	Thrombocytopenia, bleeding
Dangerous form	Lyme nephritis (kidney)	Rarely life-threatening	Chronic bone marrow suppression
Standard treatment	Doxycycline ~30 days	Doxycycline 2–4 weeks	Doxycycline 28–30 days
Vaccine available?	Yes (non-core/lifestyle)	No	No
Key geographic risk	Northeast, Upper Midwest	Northeast, Upper Midwest, Pacific NW	Southeast, South-Central

Co-infection with Lyme and anaplasmosis is common because both organisms share the blacklegged tick vector. A dog that tests positive for both on a SNAP 4Dx is not unusual in endemic areas. The clinical picture of co-infection can be more complex than either disease alone.

For how Lyme differs from leptospirosis, another environment-associated bacterial infection: leptospirosis is a different bacterium (Leptospira), transmitted through contaminated water, and is zoonotic to humans — a different risk entirely from tick-borne Borrelia.

The Lyme-positive decision flowchart

When your dog tests positive on a SNAP 4Dx, the veterinary decision path follows a structured evaluation rather than an automatic prescription:

Step 1: Clinical signs present?

• If yes (lameness, fever, joint swelling, lethargy): proceed to treatment with doxycycline for 30 days and concurrent baseline workup
• If no: proceed to screening

Step 2: Screening workup

• Complete blood count and chemistry panel
• Urinalysis with urine protein-to-creatinine ratio (UPC)
• Quantitative C6 antibody titer (QC6) — establishes a baseline number

Step 3: Proteinuria detected?

• If yes (UPC elevated above normal): even without overt clinical signs, proteinuria in a Lyme-positive dog raises concern for early Lyme nephritis. Treatment with doxycycline plus further renal workup (blood pressure, renal ultrasound, possible referral to internal medicine) is warranted.
• If no: monitor. Recheck UPC and clinical status in 6 months. Recheck QC6 in 6 months to track antibody trend.

Step 4: Follow-up monitoring

• Declining QC6 titer over 6 months suggests the immune response is resolving, whether treated or untreated
• Stable or rising QC6 titer may prompt reassessment and possible treatment
• Any new onset of lameness, fever, or proteinuria should trigger reevaluation

This flowchart reflects the ACVIM 2018 consensus and current CAPC guidance. The key principle: the test result drives screening, not automatic treatment. Treatment is triggered by clinical signs or evidence of organ involvement, not by the antibody result alone.

Tick prevention beyond medication: the physical check

While isoxazoline preventives and the Lyme vaccine form the pharmaceutical core of Lyme prevention, physical tick checking remains a valuable supplementary practice:

• Check your dog after every outdoor excursion in tick habitat — tall grass, wooded areas, leaf litter, brush margins
• Focus on high-attachment areas: ears, head, neck, between toes, armpits, groin, and the base of the tail
• Remove attached ticks promptly using fine-tipped tweezers or a tick-removal tool, grasping the tick as close to the skin as possible and pulling straight out with steady pressure. Do not twist, burn, or apply substances to the tick.
• Record the date of removal — if clinical signs develop 2 to 5 months later, knowing when the tick was attached helps the veterinarian assess timing

Physical tick checks are particularly important for dogs in high-exposure environments, thick-coated breeds where ticks can hide, and as a backup during any lapse in preventive medication coverage. No single prevention strategy is perfect, and layering strategies provides the strongest protection.

Lyme Disease in Dogs FAQs

Can a dog get Lyme disease more than once?

Yes. Natural infection does not produce reliable, long-lasting immunity. A dog that has been treated for Lyme disease can be re-exposed and potentially reinfected through subsequent tick bites. This is one reason ongoing tick prevention and annual screening remain important even after a dog has been treated.

Does a positive Lyme test mean my dog needs doxycycline right now?

Not necessarily. A positive test in a clinically healthy dog with normal bloodwork and no proteinuria may warrant monitoring rather than immediate treatment. The decision depends on clinical signs, urine protein status, and the veterinarian's assessment of the individual case. The ACVIM 2018 consensus notes that treating clinically healthy seropositive dogs is controversial.

Do the flea and tick pills (Bravecto, NexGard, Simparica) prevent Lyme disease?

They reduce the risk significantly by killing ticks, but they do not eliminate the risk of Borrelia transmission entirely. Tick-killing and Lyme vaccination are complementary strategies, especially in high-prevalence regions.

How common is Lyme disease in dogs in my state?

CAPC publishes annual prevalence maps based on millions of diagnostic test results. Seroprevalence ranges from about 1.4 percent in western states to 13.3 percent in the Northeast. Your veterinarian can assess local risk using CAPC data and regional surveillance.

Is Lyme disease contagious from my dog to me or to my other pets?

No. Lyme disease cannot be transmitted directly from dog to human or dog to dog. Transmission requires a tick vector — specifically the blacklegged tick. However, an infected dog in the household indicates that infected ticks are present in the environment, which means the human household members are also at risk from tick bites.

Should I be worried about my own Lyme risk if my dog tests positive?

Your dog's positive Lyme test is a sentinel signal. It tells you that Lyme-infected ticks are active in your environment. While your dog cannot give you Lyme disease directly, the same ticks that bit your dog can bite you. Talk to your physician about tick-bite prevention and awareness, especially if you live in or have visited an endemic area.

Sources

• Companion Animal Parasite Council (CAPC) — Lyme Disease Guidelines and Prevalence Maps. capcvet.org
• American Veterinary Medical Association (AVMA) — Lyme Disease in Dogs. avma.org
• Merck Veterinary Manual — Lyme Borreliosis in Animals. merckvetmanual.com
• Littman MP, et al. ACVIM Small Animal Consensus Statement on Lyme Disease in Dogs: Diagnosis, Treatment, and Prevention. J Vet Intern Med. 2018;32(3):887-903. ncbi.nlm.nih.gov
• Cornell Baker Institute — Lyme Disease in Dogs. cornell.edu
• openFDA Animal Adverse Event Database (export dated 2026-07-05). open.fda.gov